Nektar Therapeutics (NASDAQ:NKTR) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Head of Corporate Affairs Howard Robin - President and CEO Gil Labrucherie - COO and CFO Jonathan Zalevsky - Chief of Research and Development Dimitry Nuyten - Chief Medical Officer Conference Call Participants Jay Olson - Oppenheimer Jessica Fye - JPMorgan Daina Graybosch - SVB Leerink Arlinda Lee - Canaccord Operator Good day and thank you for standing by. Welcome to the Nek ...

Nektar Therapeutics (NASDAQ:NKTR) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Head of Corporate Affairs Howard Robin - President and CEO Gil Labrucherie - COO and CFO Dr. Jonathan Zalevsky - Chief of Research and Development Dr. Brian Kotzin - Interim CMO and Head of Development Conference Call Participants Peter Lawson - Barclays Jay Olson - Oppenheimer Jessica Fye - JPMorgan Alex Bouilloux - Mizuho Ben Burnett - Stifel Daina Graybosch - SVB Leerink Arlin ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President, Chief Executive Officer Jonathan Zalevsky - Chief Research & Development Officer Brian Kotzin - Interim Chief Medical Officer, Head of Development Gil Labrucherie - Chief Operating Officer, Chief Financial Officer Conference Call Participants Peter Lawson - Barclays Jay Olson - Oppenheimer Jessi ...

NEKTAR® SMARTER MEDICINE™ 39th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 11, 2021 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start of and plans for ongoing or planned clinical trials with partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially, and these sta ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Affairs Howard Robin - CEO, President & Director Wei Lin - SVP & Head, Development Jonathan Zalevsky - Chief Research & Development Officer Gilbert Labrucherie - SVP, CFO & COO Conference Call Participants Alexander Duncan - Piper Sandler & Co. Daniel Wolle - JPMorgan Chase & Co. George Farmer - BMO Capital Markets Alexandre Bouilloux - Mizuho Secur ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President and Chief Executive Officer Gil Labrucherie - Chief Operating Officer and Chief Financial Officer Jonathan Zalevsky - Chief, Research and Development Wei Lin - Head, Development Conference Call Participants Peter Lawson - Barclays Tyler Van Buren - Piper Sandler Chris Shibutani - Cowen Alex Lim - Mi ...

Nektar Therapeutics (NASDAQ:NKTR) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Jennifer Ruddock - SVP, Strategy & Corporate Affairs Howard Robin - President & CEO Wei Lin - SVP & Head of Development Jonathan Zalevsky - Chief R&D Officer Gil Labrucherie - COO & CFO Conference Call Participants Peter Lawson - Barclays Tyler Van Buren - Piper Sandler Chris Shibutani - Cowen Difei Yang - Mizuho Bert Hazlett - BTIG George Farmer - BMO Capital Markets Arlinda Lee - Canaccord Aydin ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2019 Results Conference Call February 27, 2020 5:00 PM ET CompanyParticipants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President and Chief Executive Officer Dr. Wei Lin - Senior Vice President and Head of Development Dr. Jonathan Zalevsky - Chief Research and Development Officer Gil Labrucherie - Chief Operating Officer and Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen Alexander Duncan - Piper ...

NEKTAR® 38th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 13, 2020 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings with the SEC i ...

NEKTAR® SMARTER MEDICINE™ Jefferies 2019 London Healthcare Conference Jonathan Zalevsky, PhD Chief R&D Officer November 20, 2019 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Ne ...